Radioimmunoassay: Principles, Uses, and Decline

The RIA reaction exploits a fundamental property of antibodies: their binding sites are finite and saturable. A standard RIA tube contains three components: a specific antibody at a concentration chosen to bind roughly 50 percent of the labelled antigen in the absence of competing analyte, a fixed quantity of antigen labelled with a radioisotope (the tracer), and the test sample or calibration standard containing unlabelled analyte.

Labelled and unlabelled antigen compete for the same binding sites. When the sample contains no analyte, essentially all bound radioactivity is from the tracer. As analyte concentration increases, unlabelled molecules displace tracer from binding sites and the radioactivity in the bound fraction falls. The relationship between bound radioactivity and analyte concentration is the basis of quantification.

After the competitive reaction reaches equilibrium, bound and free fractions must be physically separated before counting. Several separation methods have been used: activated charcoal adsorption (which adsorbs small free antigen while bound antigen-antibody complexes remain in solution), polyethylene glycol precipitation of the antibody-antigen complex, and solid-phase separation where the antibody is immobilised on the tube wall or on magnetic particles. The choice of separation method affects assay precision and throughput.

Iodine-125 is the dominant label in kit-based RIA because its gamma emission can be counted directly in a gamma counter without adding scintillation fluid, gamma counters can process hundreds of tubes per hour, and iodination chemistries for attaching 125I to proteins (via tyrosine residues using chloramine-T or iodogen reagents) are well established. The primary limitation is the 60-day half-life: kits must be used within a few months of preparation, and decay reduces sensitivity over time, requiring fresh calibrators and reagent replacement on a schedule that adds cost and waste.

Tritium (3H) is preferred when the analyte is a small molecule whose binding properties would be altered by bulky iodine substitution. Steroid hormones, thyroid hormones, and many drug molecules fall into this category. Tritium-labelled steroids behave virtually identically to their natural counterparts in terms of antibody binding. The 12.3-year half-life of tritium gives reagents a long working life. The trade-off is that beta particles from tritium require liquid scintillation counting, which is slower than gamma counting, produces liquid scintillant waste requiring separate disposal, and is more labour-intensive.

All work with radioactive materials requires a licence from the relevant national regulatory authority. In the United States this is the Nuclear Regulatory Commission (NRC) or an Agreement State equivalent; in the United Kingdom it is the Environment Agency under the Environmental Permitting Regulations; in India it is the Atomic Energy Regulatory Board (AERB) under the Atomic Energy Act 1962. EU member states implement EURATOM Directive 2013/59 requirements through national legislation. These licences mandate designated radioactive work areas, personal dosimetry for workers, records of isotope use and decay, and approved disposal pathways for radioactive waste. The compliance overhead is one reason why smaller forensic laboratories discontinued RIA when non-radioactive alternatives became available.

The introduction of commercial RIA kits for drugs of abuse screening in the early 1970s marked the first time that forensic and clinical laboratories could screen for opiates, cannabinoids, and amphetamines in urine at concentrations relevant to post-dose detection windows. The EMIT (enzyme-multiplied immunoassay technique) system from Syva Corporation and 125I-based RIA kits were the dominant approaches through the 1970s and 1980s.

Forensic toxicologists used RIA as a two-stage strategy. The first stage was a screen: urine or blood was tested with RIA kits targeting drug classes (opiates, cannabinoids, cocaine metabolites, benzodiazepines, amphetamines). Negative screens were reported as negative. Positive screens were subjected to a second-stage confirmatory test, typically gas chromatography-mass spectrometry (GC-MS), which identified the specific compound and provided a quantitative result unaffected by antibody cross-reactivity. This screen-then-confirm model, established with RIA, became the standard two-tier protocol that continues today with ELISA or CLIA as the screening step.

RIA was also applied in forensic serology research during this period, particularly in studies of species-specific protein markers and in early work on ABO blood group antigens in dried stains. These applications were largely research-oriented rather than casework-routine, given the cost and complexity of running RIA in a serology laboratory alongside conventional precipitin and agglutination methods. For a broader picture of the immunological methods used in body-fluid identification, see the history of forensic serology and immunology.

Enzyme-linked immunosorbent assay (ELISA) replaced RIA as the dominant immunoassay format in most forensic and clinical laboratories during the 1990s. ELISA replaces the radioisotope tracer with an enzyme label (most commonly horseradish peroxidase or alkaline phosphatase) whose reaction with a substrate produces a coloured or fluorescent product measured by a photometer. The sensitivity of ELISA for most small-molecule analytes is within a factor of two to five of RIA, which is sufficient for practical screening at forensic cutoff concentrations.

Chemiluminescent immunoassay (CLIA) became the platform of choice on automated immunoassay analysers from the 2000s onward. CLIA uses enzyme-substrate pairs that generate light rather than colour, eliminating the spectrophotometric interference that affects ELISA in heavily pigmented or haemolysed samples. Modern CLIA platforms such as the Abbott ARCHITECT, Roche Cobas, and Siemens ADVIA systems process hundreds of samples per hour with minimal manual steps, at a cost per test substantially below historical RIA kit costs.

The specificity limitation shared by all immunoassays, including RIA, ELISA, and CLIA, is antibody cross-reactivity. None of these formats can definitively distinguish the target analyte from structurally related compounds. The two-stage screen-confirm protocol, where positive immunoassay screens are confirmed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) or GC-MS, remains mandatory in forensic toxicology regardless of which immunoassay platform is used for screening. This is codified in guidelines from bodies including SAMHSA (Substance Abuse and Mental Health Services Administration) in the United States, the UK's Forensic Science Regulator, and the Society of Forensic Toxicologists (SOFT).

The withdrawal of RIA from routine forensic laboratory work was driven by several converging factors, not a single technical failure. Understanding these factors clarifies both why RIA dominated when it did and why its replacement was economically and practically rational.

• Radioactive materials regulation. Operating a licensed radioactive materials facility requires designated laboratory space, trained radiation safety officers, personal dosimetry for staff, sealed waste containers, approved disposal contracts, and regular regulatory inspections. This infrastructure adds fixed costs that are absent from ELISA or CLIA operations. Smaller forensic laboratories found the overhead disproportionate relative to the volume of RIA testing they performed.
• Short reagent shelf-life. Iodine-125-labelled kits have a working life of roughly two to three months from calibration. A laboratory that uses RIA infrequently may discard significant quantities of expired reagent, increasing cost per test beyond what the list price suggests.
• Radioactive waste disposal. All tubes, pipette tips, and liquids that contact radioactive reagents require segregated disposal via approved contractors or in-house decay-in-storage programmes. The volume of low-level radioactive waste generated in a busy drug-screening laboratory is substantial.
• Comparable sensitivity from non-radioactive methods. Once ELISA and CLIA demonstrated equivalent sensitivity at the cutoff concentrations mandated by forensic guidelines (for example, 50 ng/mL for cannabinoid metabolites under SAMHSA guidelines), the technical argument for RIA's sensitivity advantage in routine screening collapsed.
• Automation and throughput. Modern CLIA analysers automate sample loading, incubation, washing, signal measurement, and result interpretation. Equivalent automation was never achieved for RIA at comparable scale, meaning RIA remained more labour-intensive per test than the platforms that replaced it.

The transition was not immediate or simultaneous across all countries. Laboratories in jurisdictions with stringent disposal requirements (such as Germany and the Netherlands) moved away from RIA earlier than those with less demanding waste regulations. In some lower-resource settings, RIA kits with long-lived tritium labels continued to be used into the 2000s because their lower per-kit cost and long shelf-life made them more practical than automated CLIA platforms with high capital costs.

The decline of RIA in routine forensic laboratories does not mean the method is obsolete. Several contexts justify its continued use.

Reference and method validation laboratories use RIA as a benchmark. When a new ELISA or CLIA kit is introduced for a drug or hormone previously quantified by RIA, regulatory validation submissions typically require a method comparison demonstrating that the new assay performs equivalently to the established RIA. The US Food and Drug Administration's bioanalytical method validation guidance and the European Medicines Agency's equivalent document both accept RIA data as a reference standard in pharmacokinetic studies. For these regulatory comparisons, an institution must maintain or have access to a validated RIA method.

Research applications involving novel analytes benefit from RIA when no commercial ELISA kit exists and the researcher needs to quantify low-abundance peptides, hormones, or biomarkers. Developing a new ELISA requires producing a labelled detection antibody and optimising a sandwich format; developing an RIA for a protein antigen may be faster if iodination chemistry is already in place and a specific antibody is available.

Some endocrinology reference laboratories retain RIA for specific assays, such as certain aldosterone, renin, and parathyroid hormone fractions, where the RIA format is considered to have fewer matrix interference issues than the available CLIA alternatives. In forensic endocrinology cases (for example, suspected performance-enhancing drug use or hormonal poisoning), reference laboratory RIA results may be cited in expert testimony. For the broader context of immunological methods in forensic body-fluid analysis, see immunology in forensic science.